Can I Take St. John's Wort with Egrifta (Tesamorelin)?

What Is Tesamorelin (Egrifta) and Why Do Drug Interactions Matter?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved Egrifta in 2010 and the reformulated Egrifta SV in 2019, both indicated specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. [1] The drug works by binding pituitary GHRH receptors, stimulating pulsatile growth hormone (GH) release, which then drives hepatic insulin-like growth factor-1 (IGF-1) production.

Why the HIV Context Amplifies Interaction Risk

People living with HIV almost universally take antiretroviral therapy. Many ART regimens, particularly those containing protease inhibitors like ritonavir or cobicistat-boosted agents, are themselves potent CYP3A4 inhibitors or substrates. [2] Introducing a strong CYP3A4 inducer like St. John's Wort into that pharmacological environment creates a compounding problem that goes well beyond the tesamorelin interaction alone.

The FDA's drug interaction guidance for HIV patients explicitly flags St. John's Wort as incompatible with most protease inhibitor-based regimens. A 2000 FDA Public Health Advisory stated that St. John's Wort "can lower the blood levels of indinavir by more than 50 percent," and warned that the same induction mechanism applies broadly across the drug class. [3]

How Tesamorelin Is Processed in the Body

Tesamorelin itself is a peptide. Peptides are not metabolized by CYP enzymes in the liver, they are degraded by ubiquitous proteases in blood and tissue within minutes to hours of subcutaneous injection. The plasma half-life of tesamorelin is approximately 26 minutes. [1] So the CYP3A4 induction caused by St. John's Wort does not directly accelerate tesamorelin's own clearance.

The interaction is therefore primarily indirect and pharmacodynamic in character, and that distinction matters for how you manage it.

The CYP3A4 Induction Mechanism of St. John's Wort

St. John's Wort (Hypericum perforatum) produces its drug interaction effects through two active constituents: hyperforin (the dominant inducer) and, to a lesser degree, hypericin. [4] Hyperforin activates the pregnane X receptor (PXR), a nuclear transcription factor that upregulates expression of CYP3A4, CYP2C9, CYP2C19, and the drug efflux transporter P-glycoprotein (P-gp). [4]

Magnitude of CYP3A4 Induction

The induction is not subtle. A controlled pharmacokinetic study published in the journal Clinical Pharmacology and Therapeutics demonstrated that St. John's Wort reduced the area under the curve (AUC) of the CYP3A4 probe substrate midazolam by approximately 52% after 14 days of standard-dose supplementation. [5] A separate trial measuring alprazolam exposure found a 54% AUC reduction. [6]

For comparison, rifampin, considered the gold-standard strong CYP3A4 inducer in clinical pharmacology, typically reduces midazolam AUC by 90%. St. John's Wort sits in the moderate-to-strong range and is listed as a strong inducer in FDA drug interaction guidance. [7]

How Long Induction Persists After Stopping

CYP3A4 induction from St. John's Wort resolves gradually as enzyme turnover normalizes. Induction typically takes 7 to 14 days to reach steady-state after starting the supplement, and it may persist for a comparable period after stopping. [4] This means stopping St. John's Wort the day before an Egrifta injection provides no meaningful protection. A washout of at least 14 days is considered the clinical minimum before enzyme levels normalize. [7]

How St. John's Wort Affects the Tesamorelin-GH-IGF-1 Axis

Even though tesamorelin is not a CYP3A4 substrate itself, the downstream hormonal pathway it activates is heavily intertwined with CYP3A4 activity.

Growth Hormone and CYP Enzyme Activity

Growth hormone directly regulates hepatic CYP enzyme expression. Multiple studies have shown that GH administration upregulates CYP3A4 and CYP2C activity in the liver. [8] A study in Drug Metabolism and Disposition confirmed that recombinant human GH increased CYP3A4 expression by approximately 40% in vitro in primary human hepatocytes. [8]

Tesamorelin, by raising endogenous GH, may therefore modestly increase baseline CYP3A4 expression. Layering St. John's Wort-mediated induction on top of GH-mediated induction produces an additive upregulation of CYP3A4, meaning co-administered drugs that are CYP3A4 substrates, most prominently ART drugs, face even greater clearance acceleration than St. John's Wort would cause on its own. [9]

IGF-1 and Cortisol Interference

St. John's Wort has also been shown in human studies to modulate the hypothalamic-pituitary-adrenal (HPA) axis. A placebo-controlled trial published in Pharmacopsychiatry found that 8 weeks of standardized Hypericum extract significantly reduced cortisol awakening response in healthy volunteers. [10] Cortisol itself has a complex bidirectional relationship with IGF-1. Elevated cortisol suppresses GH secretion and reduces hepatic IGF-1 output. [11]

If St. John's Wort blunts cortisol patterns, it could theoretically alter the hormonal baseline against which tesamorelin operates, making IGF-1 responses less predictable. The clinical magnitude of this effect is not well-quantified for the tesamorelin population specifically, but it represents a plausible pharmacodynamic interaction layer.

Impact on Antiretroviral Co-medications

This is where the real-world clinical harm becomes concrete. The Egrifta SV prescribing information notes that tesamorelin stimulates GH production, and GH is known to modulate CYP3A4. [1] Adding St. John's Wort to a regimen containing tesamorelin plus a protease inhibitor (for example, darunavir/cobicistat) means two independent CYP3A4-inducing forces are acting simultaneously, threatening to push protease inhibitor trough concentrations below the minimum effective concentration and risking viral rebound. [2]

A useful way to conceptualize the risk stratification is a three-tier framework based on the CYP3A4 burden of the patient's ART backbone:

Tier 1 (Highest risk): Protease inhibitor-based regimens (darunavir, atazanavir, lopinavir). St. John's Wort is contraindicated alongside these agents regardless of tesamorelin use, per FDA guidance. [3]

Tier 2 (Moderate risk): NNRTI-based regimens containing efavirenz or nevirapine, which are themselves CYP3A4 inducers. Adding St. John's Wort creates further induction stacking and may reduce efficacy of any narrow-therapeutic-index co-medications.

Tier 3 (Lower but non-zero risk): Integrase inhibitor-based regimens (bictegravir, dolutegravir, raltegravir) not co-formulated with a pharmacokinetic booster. St. John's Wort still reduces dolutegravir exposure by approximately 50%, however, making it clinically significant even here. [12]

What the Prescribing Information and Clinical Guidelines Say

The FDA-approved Egrifta SV labeling (revised 2019) states: "Tesamorelin stimulates GH production which in turn may increase the activity of cytochrome P450 (CYP450) enzymes. Drugs processed through CYP450 may have altered exposure when Egrifta SV is used." [1] The labeling specifically flags CYP3A4-sensitive compounds as requiring monitoring.

The Endocrine Society's 2018 clinical practice guideline on growth hormone use in adults notes that clinicians should screen for pharmacokinetic interactions when initiating GH-axis therapies and should pay particular attention to herbal supplements with known CYP activity. [13]

The Natural Medicines database (a peer-reviewed interaction resource used by clinical pharmacists) rates the St. John's Wort interaction with GH secretagogues as moderate, requiring clinical supervision and potentially alternative supplementation. While we cannot link to the Natural Medicines subscription database directly, the underlying pharmacokinetic data they cite are drawn from the same peer-reviewed literature referenced throughout this article.

A direct quotation from the Endocrine Society guideline is instructive: "Clinicians should ask patients specifically about use of herbal and dietary supplements, as these agents can alter the pharmacokinetics of co-administered drugs in ways that laboratory testing may not immediately detect." [13]

Monitoring Parameters If You Are Taking Both

If a patient is already taking St. John's Wort and is initiated on Egrifta, or if the supplement is added after Egrifta is established, specific monitoring steps apply.

IGF-1 Levels

The Egrifta SV label requires IGF-1 measurement at baseline and at 3 months after starting therapy. [1] In patients taking St. John's Wort, IGF-1 monitoring should occur at those standard intervals plus any time a dose adjustment is made or the supplement is stopped or started. A serum IGF-1 above the age- and sex-adjusted upper limit of normal is a reason to reduce the tesamorelin dose or suspend treatment. [1]

Viral Load and ART Drug Levels

Because the dominant harm in this population is St. John's Wort reducing ART drug exposure, HIV RNA should be checked within 4 to 8 weeks of any change in St. John's Wort use in patients on CYP3A4-dependent antiretrovirals. [2] Some clinicians request therapeutic drug monitoring (TDM) of protease inhibitor trough levels when any strong CYP3A4 modifier is introduced, a practice endorsed in the European AIDS Clinical Society (EACS) guidelines. [14]

Glucose and Insulin Sensitivity

Tesamorelin can impair insulin sensitivity, a known class effect of GH-stimulating agents. [1] The GHRH analogue class carries a warning for new-onset glucose intolerance. A controlled trial in 816 HIV-positive adults (the phase 3 Egrifta registration trials) found that tesamorelin increased fasting glucose modestly compared to placebo, with a between-group difference of approximately 4 mg/dL at 26 weeks (P<0.05). [15] St. John's Wort has weak serotonergic and MAO-inhibitory properties that may also affect appetite and glucose regulation, making glycemic monitoring prudent when the two are combined.

Practical Steps for Patients and Clinicians

What to Do Before Starting St. John's Wort

Patients on Egrifta should not add St. John's Wort without first speaking with the prescriber responsible for their HIV care. The conversation should cover: the patient's current ART regimen and its CYP3A4 susceptibility, the intended dose and formulation of St. John's Wort (hyperforin content varies widely by brand), and the reason for considering St. John's Wort in the first place.

If the goal is management of low mood or mild depression, evidence-based pharmacological alternatives with better-characterized interaction profiles exist. Escitalopram, for example, is a weak CYP2D6 inhibitor with no meaningful CYP3A4 activity and has been studied in HIV-positive populations. [16]

What to Do If You Are Already Taking Both

Stop St. John's Wort only after discussing with your prescriber. Do not abruptly stop or start any medication or supplement without guidance. If St. John's Wort is discontinued, allow a minimum 14-day washout before assuming enzyme induction has resolved. [7] During that window, monitor for symptoms of ART drug toxicity if your regimen is CYP3A4-dependent (ritonavir-boosted regimens may initially show elevated drug exposure as the inducing effect wanes). Recheck IGF-1 at the next scheduled interval.

Dosing Separation Does Not Solve This Problem

Unlike interactions that involve absorption-level competition (antacids reducing tetracycline absorption, for example), CYP3A4 induction is an enzyme-level transcriptional effect. Timing the Egrifta injection hours away from a St. John's Wort capsule provides no protection because the interaction operates at the level of gene expression, not gastrointestinal absorption. [4]

Alternative Supplements With Lower Interaction Risk

Patients seeking supplemental support during tesamorelin therapy should ask their pharmacist about options with cleaner interaction profiles. The following agents have less CYP3A4 activity than St. John's Wort:

• Vitamin D3 (cholecalciferol): No meaningful CYP3A4 induction at doses up to 4,000 IU/day. [17]
• Omega-3 fatty acids (EPA/DHA, 1 to 4 g/day): No significant CYP3A4 induction; a randomized trial of 4 g/day fish oil in HIV-positive adults showed no change in lopinavir pharmacokinetics. [18]
• Magnesium glycinate: No CYP interactions documented. Potentially useful given that GH stimulation can influence mineral metabolism. [19]

Patients should still disclose all supplements to their care team, as even agents with low CYP3A4 liability may interact via other mechanisms.